Regenxbio Inc RGNX.OQ RGNX.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Rockville Maryland-based company is expected to report a 0.3% decrease in revenue to $24.125 million from $24.2 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.31 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Regenxbio Inc is $34.00, about 64.7% above its last closing price of $11.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.06 | -1.10 | -1.38 | Missed | -25.5 |
Mar. 31 2025 | 0.53 | 0.48 | 0.12 | Missed | -75.1 |
Dec. 31 2024 | -1.24 | -1.15 | -1.01 | Beat | 11.9 |
Sep. 30 2024 | -1.11 | -1.12 | -1.17 | Missed | -4.3 |
Jun. 30 2024 | -1.30 | -1.29 | -1.05 | Beat | 18.7 |
Mar. 31 2024 | -1.29 | -1.26 | -1.33 | Missed | -5.6 |
Dec. 31 2023 | -1.30 | -1.27 | -1.43 | Missed | -12.5 |
Sep. 30 2023 | -1.56 | -1.52 | -1.41 | Beat | 7.1 |
This summary was machine generated November 4 at 14:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments